5AM Partners Liquidates Skye Bioscience Stake After 14.65% Weekly Surge, Insiders Shift Risk Exposure

Insider Selling Sheds Light on Skye Bioscience’s Near‑Term Outlook

On September 22, 2026, Andrew J. Schwab – a managing member of 5AM Partners VII, LLC – executed a sizable block sale of Skye Bioscience common stock, divesting 27,612 shares at a price of $1.65. The transaction, reported under Form 4, was part of a larger series of sales by the 5AM group that culminated in the complete liquidation of the firm’s holding in the company on September 23. The timing is noteworthy: the sale occurred the day after a 14.65 % weekly gain for the stock, and coincided with a surge in social‑media buzz (≈194 %) that was largely neutral (sentiment +49).

From a valuation perspective, Skye’s share price has slumped more than 90 % over the past year, with a current price of $1.80 and a negative price‑earnings ratio of –2.58. The 5AM liquidation is therefore a short‑term signal that insiders are rebalancing their risk exposure, but it does not, by itself, presage a broader decline. The company’s market cap remains modest at $7.57 million, and its recent short‑sale activity by a New York‑based firm suggests that a small group of investors are betting on further upside (or simply hedging).

What Investors Should Take Away The 5AM sell‑off is part of a consistent pattern of large block trades by Schwab and his affiliates. Historically, Schwab has sold large positions at a wide range of prices – from $0.32 in August to $3.57 in August 2025 – but has never held a position in excess of 10 % of the company’s outstanding shares. The current liquidation reduces his stake from roughly 0.13 % to zero, signalling a temporary shift rather than a permanent exit.

For short‑term traders, the immediate impact is modest; the stock’s liquidity is limited and volatility remains high. However, the broader insider activity – with 5AM Partners VII holding 981,269 shares prior to the sale – underscores that institutional investors remain invested, albeit in a highly concentrated portfolio. If the company delivers on its pipeline milestones, the 5AM stake could rebound, creating a potential upside for all shareholders.

A Quick Look at Schwab Andrew J. Schwab’s transaction history shows a pragmatic approach: he routinely sells shares at a range of valuations, often following key corporate announcements or market moves. His most recent sales in September were executed at a price close to the intraday low (≈$1.61–$1.65), suggesting a cautious, risk‑averse stance. He has also engaged in option buying (e.g., 35,000 shares in February 2026), indicating a willingness to hold upside potential while managing downside risk. In short, Schwab appears to be a liquidity‑savvy investor who uses insider transactions to adjust exposure rather than to signal fundamental change.

Bottom Line Skye Bioscience’s insider activity, particularly the 5AM liquidation, offers a snapshot of institutional risk management rather than a definitive market forecast. Investors should monitor upcoming clinical milestones and any shifts in short‑sale volumes, which could provide early indicators of a broader market re‑evaluation. Meanwhile, the company’s current valuation, combined with the recent surge in social‑media attention, suggests that any rebound will require a clear catalyst to overcome the 94 % year‑to‑date decline.